<DOC>
	<DOCNO>NCT00189410</DOCNO>
	<brief_summary>Pegylated Liposomal Doxorubicin well Carboplatin show efficacy monotherapy combination therapy gynaecologic tumour . As common standard therapy recurrent ovarian carcinoma , tumours uterus non-epithelial ovarian tumour time design study , trial shall evaluate new well tolerate combination therapy consist Pegylated Liposomal Doxorubicin Carboplatin .</brief_summary>
	<brief_title>Combination Chemotherapy Consisting Pegylated Liposomal Doxorubicin Carboplatin Malignant Gynecologic Tumours</brief_title>
	<detailed_description>Aim study evaluation combination chemotherapy patient subset gynecologic tumour regard tolerance efficacy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically confirm diagnosis gynecologic tumour [ ( nonepithelial ovarian tumour without germcelltumours , tumour uterus ( eg . Muellerian mixed tumour , Endometrial carcinoma , Uterus sarcoma , Cancer cervix ) ] Target nontarget lesion . Patients epithelial ovarian carcinoma qualify also CA 125 increase . Patients ovarian carcinoma must complete platincontaining chemotherapy 6 month least . Patients malignancy could prior chemotherapy , must'nt Prior Radiotherapy le 25 % haemapoietic system allow , complete least 6 week prior registration Prior antitumoral hormone therapy , specific immunotherapy allow , treatment complete least 3 week prior registration All woman childbearing potential negative pregnancy test within 7 day registration Perfomance Status 02 ECOG 60 % accord Karnofsky Index Estimated expectancy life 12 week adequate hematologic , renal hepatic function accord follow definition : absolute Neutrophils &gt; = 1,5 n/L Platelets &gt; = 100 n/L Bilirubine &lt; = 1,25 x ULN estimate glomerular filtration rate ( Jelliffe ) &gt; = 60 ml/min Patients give sign write informed consent participate trial Patients must geographically accessible treatment follow More 2 prior chemotherapy ( RadioChemotherapies ) active infection concurrent severe medical problem unrelated malignancy would significantly limit full compliance study expose patient extreme risk decrease life expectancy application cytotoxic antitumoral agent study period Patients history seizure disorder central nervous system disorder History congestive heart failure ( NYHA Classification &gt; 2 , even medically control . History clinical electrocardiographically document myocardial infarction within last 6 month . History atrial ventricular arrhythmia ( &gt; LOWN II ) Women pregnant breast feed Fertile woman use adequate contraceptive measure Patients use investigational drug within 30 day study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>